India OKs Edict-Par $38m acquisition, but policy on larger deals still unclear
This article was originally published in Scrip
India's Foreign Investment Promotion Board (FIPB) has cleared a clutch of foreign acquisitions of domestic firms, setting aside general concerns that the recently modified approval route for such proposals may involve greater scrutiny, pose delays and hurt investments in the sector.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.